| Literature DB >> 29843603 |
Eli Grindflek1, Marianne H S Hansen2,3, Sigbjørn Lien3, Maren van Son2.
Abstract
BACKGROUND: Umbilical hernia is one of the most prevalent congenital defect in pigs, causing economic losses and substantial animal welfare problems. Identification and implementation of genomic regions controlling umbilical hernia in breeding is of great interest to reduce incidences of hernia in commercial pig production. The aim of this study was to identify such regions and possibly identify causative variation affecting umbilical hernia in pigs. A case/control material consisting of 739 Norwegian Landrace pigs was collected and applied in a GWAS study with a genome-wide distributed panel of 60 K SNPs. Additionally candidate genes were sequenced to detect additional polymorphisms that were used for single SNP and haplotype association analyses in 453 of the pigs.Entities:
Keywords: GWAS; Genome-wide association study; Hernia; LIF; OSM; Pigs; Umbilical
Mesh:
Year: 2018 PMID: 29843603 PMCID: PMC5975507 DOI: 10.1186/s12864-018-4812-9
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Eight positional and/or biological candidate genes were used for resequencing
| Gene name | Positiona | References |
|---|---|---|
| Leukemia inhibitory factor (LIF) | 14:50263722–50,266,807 | [ |
| Oncostatin M (OSM) | 14:50281701–50,286,188 | [ |
| Macrophage migration inhibitory factor (MIF) | 14:53282552–53,283,339 | [ |
| Cyclin-dependent kinase inhibitory protein p57KPI2 (CDKN1C) | Unplaced | [ |
| Pyrroline-5-carboxylate reductase 1 (PYCR1) | Unplaced | [ |
| Versican (VCAN) | 2:93783042–93,895,497 | [ |
| Matrix metallopeptidase 13 (MMP13) | 9:37493636–37,504,552 | [ |
| Vimentin (VIM) | 10:48227005–48,235,670 | [ |
aPositions are in chromosome:basepairs
SNPs within candidate genes used for association analysis
| Gene Name | SNP name | Location | Allelesa | MAFb | Pc | %vard |
|---|---|---|---|---|---|---|
| Versican | VCAN_1 | Exon 8 | A/ | 0.45 | n.s. | 0.2 |
| Versican | VCAN_2 | Exon 8 | G/ | 0.45 | n.s. | 0.4 |
| Versican | VCAN_3 | Exon 8 | T/ | 0.45 | n.s. | 0.4 |
| Versican | VCAN_4 | Exon 8 | C/ | 0.45 | n.s. | 0.2 |
| Versican | VCAN_5 | Exon 8 | 0.38 | n.s. | 0.4 | |
| Versican | VCAN_6 | Exon 8 | C/ | 0.38 | n.s. | 0.4 |
| Leukemia inhibitory factor | LIF_1 | Intron 1 | 0.47 | 0.001 | 8.6 | |
| Matrix metallopeptidase 13 | MMP13_1 | Intron 7 | 0.33 | n.s. | 0.08 | |
| Matrix metallopeptidase 13 | MMP13_2 | Intron 7 | 0.33 | n.s. | 0.05 | |
| Matrix metallopeptidase 13 | MMP13_3 | Exon 8 | 0.33 | n.s. | 0.1 | |
| Matrix metallopeptidase 13 | MMP13_4 | Intron 8 | 0.33 | n.s. | 0.03 | |
| Matrix metallopeptidase 13 | MMP13_5 | Intron 8 | 0.32 | n.s. | 0.01 | |
| Matrix metallopeptidase 13 | MMP13_6 | Intron 8 | 0.33 | n.s. | 0.3 | |
| Oncostatin M | OSM_1 | Exon 3 | 0.47 | 0.001 | 7.7 | |
| Oncostatin M | OSM_2 | Exon 3 | 0.47 | 0.001 | 8.6 | |
| Oncostatin M | OSM_3 | Exon 3 | 0.47 | 0.001 | 8.6 | |
| Oncostatin M | OSM_4 | Exon 3 | 0.47 | 0.0008 | 8.6 | |
| Oncostatin M | OSM_5 | Exon 3 | 0.47 | 0.001 | 8.6 | |
| Oncostatin M | OSM_6 | Intron 3 | 0.47 | 0.001 | 7.7 | |
| Oncostatin M | OSM_7 | Intron 3 | 0.47 | 0.001 | 7.7 | |
| Oncostatin M | OSM_8 | Intron 3 | 0.47 | 0.001 | 7.7 | |
| Pyrroline-5-carboxylate reductase 1 | PYCR1_1 | 5’ UTR | 0.11 | n.s. | 2.5 | |
| Pyrroline-5-carboxylate reductase 1 | PYCR1_2 | 5’ UTR | 0.13 | n.s. | 1.0 | |
| Pyrroline-5-carboxylate reductase 1 | PYCR1_3 | Intron 1 | 0.03 | n.s. | 1.0 | |
| Vimentin | VIM_1 | Intron 5 | C/ | 0.21 | n.s. | 0.2 |
| Vimentin | VIM_2 | Intron 5 | A/ | 0.36 | n.s. | 0.3 |
| Vimentin | VIM_3 | Intron 5 | C/ | 0.17 | n.s. | 0.01 |
| Vimentin | VIM_4 | Intron 5 | A/ | 0.19 | n.s. | 0.6 |
| Vimentin | VIM_5 | Intron 5 | C/ | 0.15 | n.s. | 0.00 |
| Vimentin | VIM_6 | Intron 5 | C/ | 0.34 | n.s. | 0.3 |
| Vimentin | VIM_7 | Intron 5 | C/ | 0.11 | n.s. | 0.7 |
amajor/minor allele, where risk allele is indicated in bold
bminor allele frequency (MAF)
cp-value (p > 0.001 is n.s)
dthe percentage of explained phenotypic variance (%var)
Fig. 1Manhattan plot of genome-wide association results. The x axis represents the genome in physical order whereas the y axis shows –log10 p-value for all SNPs. The line corresponds to a significance level of P < 0.001
The most significant 60 k SNPs for umbilical hernia
| Marker name | SSC | Position | MAFa | %varc | |
|---|---|---|---|---|---|
| INRA0043998 | 14 | 50,652,198 | 0.48 | 7.43e-05 | 8.1 |
| ASGA0063261 | 14 | 50,672,335 | 0.48 | 7.43e-05 | 8.1 |
| ASGA0063262 | 14 | 50,738,530 | 0.48 | 7.43e-05 | 8.1 |
| ALGA0077446 | 14 | 50,761,608 | 0.48 | 7.43e-05 | 8.1 |
| ASGA0063267 | 14 | 50,776,775 | 0.48 | 7.43e-05 | 8.1 |
| ALGA0077450 | 14 | 50,792,395 | 0.48 | 7.43e-05 | 8.1 |
| MARC0024032 | 14 | 50,824,208 | 0.48 | 7.43e-05 | 8.1 |
| INRA0044003 | 14 | 50,847,851 | 0.48 | 7.43e-05 | 8.1 |
| MARC0112737 | 14 | 50,917,403 | 0.48 | 7.43e-05 | 8.1 |
| ALGA0077457 | 14 | 50,938,144 | 0.48 | 7.43e-05 | 8.1 |
| ASGA0063274 | 14 | 50,964,903 | 0.48 | 7.43e-05 | 8.1 |
| H3GA0040130 | 14 | 50,992,818 | 0.50 | 7.43e-05 | 7.9 |
| ASGA0063217 | 14 | 49,288,281 | 0.49 | 9.21e-05 | 8.6 |
aminor allele frequency (MAF)
bthe genomic control corrected p-value
cthe percentage of explained phenotypic variance (%var)
Fig. 2Association results for SSC14. a A QTL region of 62 SNPs on SSC 14 reached a significance level of P < 0.00015 (solid line) and they were localized between 48.04 and 50.99 Mb. b Map of characterized genes in the QTL region and their orientation, based on information available from Ensembl, where candidate genes are indicated in red. c An LD plot was constructed using Haploview for the QTL region. R2 was used as a measurement of LD, where a darker color represents a higher R2 value. The red triangle covers the SNPs in the candidate genes and they are all in complete LD
Results from the haplotype analyses
| Gene name | #haplotypesa | % Varb | |
|---|---|---|---|
| Versican (VCAN) | 7 | 0.03 | 0.1 |
| Matrix metallopeptidase 13 (MMP13) | 5 | 0.04 | 0.02 |
| Oncostatin M (OSM) | 2 | 0.0012 | 6.0 |
| Pyrroline-5-carboxylate reductase 1 (PYCR1) | 6 | 0.03 | 0.07 |
| Vimentin (VIM) | 11 | 0.13 | 0.1 |
ahaplotypes were constructed within genes based on SNPs in Table 2 and are presented with the number of haplotypes with a frequency > 2%
bthe percentage of explained phenotypic variance